

## Anais: II Seminário de Iniciação Científica

# PLATAFORMA INTELIGENTE PARA ONCOLOGIA DE PRECISÃO SEM O USO DE BIOMARCADORES

## SMART PLATFORM FOR BIOMARKER-FREE PRECISION ONCOLOGY WITHOUT THE USE OF BIOMARKERS

Ana Beatriz Ramos Do Nascimento

Afiliação: Federal University of Minas Gerais, Department of Physics; Teaching, Research, and Innovation Center of the Mário Penna Institute.  
ORCID: <https://orcid.org/0009-0006-6941-6428>  
e-mail: [anabeatrizramosnascimento.2003@gmail.com](mailto:anabeatrizramosnascimento.2003@gmail.com)

Pedro Henrique Villar Delfino

Afiliação: Startup OncoTag  
ORCID: <https://orcid.org/0000-0003-4755-0950>  
e-mail: [pedrohvillar@hotmail.com](mailto:pedrohvillar@hotmail.com)

Paulo Guilherme de Oliveira Salles

Afiliação: Teaching, Research, and Innovation Center of the Mário Penna Institute.  
ORCID: <https://orcid.org/0000-0001-8839-3491>  
e-mail: [sallespgo@hotmail.com](mailto:sallespgo@hotmail.com)

Paulo Henrique Ribeiro Amaral

Afiliação: Federal University of Minas Gerais, Department of Physics.  
ORCID: <https://orcid.org/0000-0003-0799-4143>  
e-mail: [phramaral@gmail.com](mailto:phramaral@gmail.com)

Letícia da Conceição Braga

Afiliação: Startup OncoTag; Teaching, Research, and Innovation Center of the Mário Penna Institute.  
ORCID: <https://orcid.org/0000-0002-6181-9410>  
e-mail: [braga.ltc@gmail.com](mailto:braga.ltc@gmail.com)

Juan Carlos Gonzáles Pérez

Afiliação: Federal University of Minas Gerais, Department of Physics.  
ORCID: <https://orcid.org/0000-0001-9155-1657>  
e-mail: [gonzalez@fisica.ufmg.br](mailto:gonzalez@fisica.ufmg.br)

Data de submissão: 17/06/2024.

Data de aprovação: 18/06/2024.

## RESUMO

### 1. INTRODUCTION

Breast cancer is considered the most common neoplasm among women, with approximately 74,000 cases estimated in Brazil for the year 2023<sup>(1,5)</sup>. Given the complexity of this neoplasm, the therapeutic approach depends on the stage of the disease and the specific type of tumor identified<sup>(2)</sup>. Complete surgical resection with clear margins of the tumor is crucial for a better prognosis for the patient<sup>(3,4)</sup>. Careful evaluation of the margins during surgery is essential for successful treatment and to prevent cancer recurrence. Therefore, there is a need to improve strategies that contribute to the removal of tumors with cancer-free margins.

### 2. OBJECTIVE

This project aims to clinically validate the tumor classification model called "Process for Classifying Cells by Lineage and Use," which utilizes

spectroscopic measurements obtained from the interaction of radiation with biological cell samples. These measurements will be processed by an artificial intelligence model to differentiate cell lineages and detect various cancerous lineages.

### 3. MATERIALS AND METHODS

Tumor tissue will be fixed in buffered formalin and subsequently embedded in paraffin to form blocks. Then, six sections of 3 to 4 micrometers in thickness will be made and placed on slides, with one stained with Hematoxylin and Eosin and the others analyzed by spectroscopy<sup>(6)</sup>. Patient data will be collected via electronic medical records and correlated with the obtained analyses. Finally, the data will be analyzed using artificial intelligence and machine learning to generate an intelligent predictive system<sup>(7)</sup>. This study was approved by the institutional ethics committee CAAE: 70737223.0.0000.5121.

### 4. PRELIMINARY RESULTS

To date, a biorepository of 22 patients, representative of normal and paired tumor tissue, has been obtained, totaling 132 slides.

### 6. CONCLUSION

Spectroscopy analysis may contribute to optimizing the characterization of surgical margins for breast cancer patients, improving prognosis, and reducing the process costs and time required for diagnosis.

**Palavras-chave:** Breast cancer; Spectroscopy; Artificial intelligence; Surgical Margins; Machine Learning.

### REFERÊNCIAS

1. Ministério da Saúde Instituto Nacional de Câncer José Alencar Gomes da Silva Ministério da Saúde Instituto Nacional de Câncer [Internet]. 2022. Available from: <https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/estimativa-2023.pdf>.

2. Vicini FA, Kestin L, Huang R, Martinez A. Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy? *Cancer*. 2003 Feb 3;97(4):910–9.
3. Jobsen JJ, van, Ong F, Meerwaldt JH. Differences in outcome for positive margins in a large cohort of breast cancer patients treated with breast-conserving therapy. *Acta Oncologica*. 2007 Jan 1;46(2):172–80.
4. Wöckel A, Albert US, Janni W, Scharl A, Kreienberg R, Stüber T. Clinical practice guideline: The screening, diagnosis, treatment, and follow-up of breast cancer. *Deutsches Aerzteblatt Online*. 2018 May 4.
5. Outubro Rosa 2023 [Internet]. Instituto Nacional de Câncer - INCA. [cited 2024 Jan 12]. Available from: <https://www.gov.br/inca/pt-br/assuntos/campanhas/2023/outubro-rosa#:~:text=O%20C%C3%A2ncer%20de%20ma>.
6. Espectroscopia [Internet]. astro.if.ufrgs.br. [cited 2024 Jan 12]. Available from: <http://astro.if.ufrgs.br/telesc/espectroscopia.html#:~:text=Em%20uma%20imagem%20%C3%B3ptica%20em>.
7. Amaral PHR, González Pérez JC, de Andrade LM. Processo para classificação de células quanto à linhagem celular e uso. Departamento de Física da UFMG.

Financial support: CNPq; Startup OncoTag; Teaching, Research, and Innovation Center of the Mário Penna Institute.

# HEMO insights

AstraZeneca 

## Uma iniciativa disruptiva para o universo da Hematologia

O **Hemo Insights**, projeto apresentado no **AZHemato**, uma iniciativa inovadora projetada para transformar a forma como os especialistas em Hematologia acessam e compartilham conhecimento.



Criamos um portal digital, repleto de conteúdos e serviços que **auxiliarão os hematologistas em seu desenvolvimento científico contínuo.**

Nosso objetivo é democratizar o conhecimento em Hematologia, tornando a plataforma acessível a todos os profissionais da área, desde iniciantes até especialistas.

**Junte-se a nós na missão de expandir as fronteiras da ciência. Venha explorar tudo o que o projeto tem a oferecer e conecte-se com o futuro da Hematologia!**

